newsfilter
← Latest News
Business Wire·

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022

U.S. Food and Drug Administration (FDA) clears protocol amendment to conduct an interim utility analysis of pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML) Blinded pooled